| 1 |
Corona vaccines, efficacy, types, etc |
Prof Kshitish K Acharya |
23mins 24secs |
275 |
27 |
1 |
2021 Jan 17 |
5 |
Easy |
5 |
Simplified explaination of Covid-19 vaccines and the necessity for vaccination |
Public health |
2021 Jan 29 |
| 2 |
Reasons for varied responses to Corona. And, the best way to prevent deaths due to Covid19 |
Prof Kshitish K Acharya |
9mins 06sec |
437 |
55 |
- |
2020 Oct 21 |
5 |
Easy |
5 |
Dr. Kshitish explains in a simplified way why there is a varied response to SARS-CoV-2 infection |
Public health |
2021 Jan 29 |
| 3 |
Scientific information about corona virus: simple straight science part I (English |
Prof Kshitish K Acharya |
16mins 12secs |
484 |
63 |
0 |
2020 Aug 15 |
5 |
Easy |
5 |
Simplified explaintion about viruses in general and how they make their entry into the cell. |
Basic science |
2021 Apr 09 |
| 4 |
Ayurveda vs. Modern medicine: Simple Straight Science, part 2 [ENGLSIH] |
Prof Kshitish K Acharya |
15mins 19secs |
309 |
50 |
0 |
2020 Aug 15 |
5 |
Easy |
5 |
Dr.Kshitish Acharya talks about the basic difference between Ayurveda and Modern Medicine |
Traditional medicin |
2021 Apr 09 |
| 5 |
COVID and the ACE-2 surface protein |
Doctor Klioze |
13 min 19 secs |
213K |
4.1K |
99 |
2020 May 03 |
5 |
OK |
5 |
Introduction to ACE2 |
ACE2 |
2021 Jan 30 |
| 6 |
How to tell if we're beating COVID-19 |
minutephysics |
7 mins 16 secs |
6.1M |
150K |
5.7K |
2020 Mar 27 |
5 |
Easy |
5 |
Epidemiological statistics, understanding increasing number of cases |
Epidemiology-Statistics |
2021 Jan 30 |
| 7 |
The Coronovirus explained & what you should do |
Kurzgeesagt-In a Nutshell |
8mins,34sec |
2.8 crore |
9.3 lakh |
13K |
2020 Mar 19 |
5 |
Very easy |
5 |
An early overview of the virus, mechanism of transmission and sickness, and management |
SARS-CoV-2, transmission and Covid-19 |
2021 Jan 30 |
| 8 |
COVID -19 Annimation: What happens if you get coronavirus? |
Nucleus Medical Media |
7min,27sec |
2 crore |
2.1 lakh |
10K |
2020 Mar 28 |
5 |
Very easy |
5 |
A good general introduction to the virus and infection |
SARS-CoV-2 and Covid-19 |
2021 Jan 30 |
| 9 |
Recognizing Day to Day Signs and Symptoms of coronavirus |
FreeMedEducation |
3min,50sec |
1 crore |
89K |
5.8K |
2020 Apr 25 |
5 |
Very easy |
5 |
Day to Day symptoms of corona virus |
Symptoms |
2021 Jan 30 |
| 10 |
Coronavirus SARS-CoV-2 structure |
Biolution |
2min,16sec |
390715 |
3.5K |
143 |
2020 Mar 13 |
5 |
Easy |
5 |
A good overview of structure of the virus and its contents |
SARS-CoV-2 |
2021 Jan 30 |
| 11 |
Coronavirus / SARS CoV-2 |
Hussain Biology |
5 min, 17 sec |
1,91,,286 |
2.6K |
149 |
2020 Feb 26 |
5 |
OK |
4 |
Introduction to the varieties of the Coronaviruses |
Corona virus types |
2021 Jan 30 |
| 12 |
SARS-COV-2 Life cycle (Summer 2020) |
RCSBProteinDataBank |
4 min, 21 sec |
6.4K |
159 |
2 |
2020 Oct 01 |
5 |
Technical information |
5 |
Lytic cycle of the virus, with introduction to its gene & proteins |
Lytic cycle, genes and proteins |
2021 Jan 30 |
| 13 |
Inside the lab that invented the Covid-19 vaccine |
It's Okay to be smart |
11 mins 50 secs |
828K |
36K |
1.2K |
2020 Dec 08 |
4 |
Easy |
5 |
Description of production of vaccine of one type at the University of Texas. Includes good introduction of cryo-electronic microscopic determination of protein structure. |
Vaccine production |
2021 Jan 30 |
| 14 |
How the SARS-COV-2 Virus Promotes Pain Relief |
University of Arizona health science |
2 min, 05 sec |
1119 |
15 |
0 |
2020 Oct 01 |
5 |
OK |
5 |
Mechanism of pain-insensitivity induced by Sars-Cov-2 |
Pain insensivity |
2021 Jan 30 |
| 15 |
SARS-CoV-2 IgG antibodies and why the receptor-biding domain of the spike protein is so important |
Beckman Coulter Dx |
2 min, 52 sec |
7791 |
92 |
0 |
2020 May 26 |
3 |
OK |
4 |
About the IGg antibodies produced from the infection and process |
Antibodies |
2021 Jan 30 |
| 16 |
COVID-19 and CD147 - An Alternative Receptor For SARS-CoV-2 |
Rahul's Advanced Biology |
10mins,37sec |
1634 |
83 |
0 |
2020 May 24 |
5 |
Technical information |
5 |
Characteristics of CD 147, an alternative route for Sars-Cov-2 |
CD147 |
2021 Jan 30 |
| 17 |
Vitamin-D & COVID 19 : The evidence for prevention & treatment of coronavirus (SARS CoV 2) |
MedCram - Medical Lectures Explained CLEARLY |
1 hr 23 secs |
2.9M |
57K |
1.6K |
2020 Dec 11 |
4 |
Technical information |
5 |
An interview on the role of vitamin D |
Vitamins |
2021 Jan 30 |
| 18 |
Covid vaccines |
Doctor Klioze |
14min 29secs |
11200 |
309 |
1 |
2020 Dec 08 |
5 |
OK |
5 |
Immunity concepts and RNA vaccines |
Vaccine |
2021 Jan 30 |
| 19 |
Covid anatomy explained:Science,simplified |
Hailee perrett |
2 min 01secs |
42820 |
306 |
17 |
2020 May 14 |
5 |
OK |
5 |
Parts of coronavirus |
Anatomy |
2021 Jan 30 |
| 20 |
Introducing SARS-CoV-2: learn the basic principles behind this virus. |
Medmastery |
4mins 34 secs |
8145 |
130 |
9 |
2020 May 27 |
5 |
Technical information |
5 |
basic microbiology of SARS-CoV-2 and describe its structural components. |
basic microbiology of SARS-CoV-2 |
2021 Jan 22 |
| 21 |
How do ventilators work? - Alex Gendler |
TED-Ed |
5mins 31 secs |
703046 |
21K |
258 |
2020 May 21 |
3 |
Technical information |
5 |
Expalins the working of ventilators , one of the main equipment used in treating ICU Covid patients |
Treatment |
2021 Jan 22 |
| 22 |
Which is better: Soap or hand sanitizer? - Alex Rosenthal and Pall Thordarson |
TED-Ed |
6mins 14sec |
2.8million |
46K |
1.2K |
2020 May 05 |
5 |
Easy |
5 |
Explains how washing hands with soap will protect us from the viral infection |
Treatment |
2021 Jan 22 |
| 23 |
SARS-CoV-2 (Covid-19) Infection Process |
CanalDivulgación |
2mins 20sec |
23707 |
251 |
16 |
2020 May 07 |
4 |
Technical information |
4 |
SARS-CoV-2 (Covid-19) Infection Process |
molecular biology |
2021 Jan 22 |
| 24 |
Biology of SARS-CoV-2: Infection |
Biointeractive |
2mins 42 sec |
13404 |
112 |
5 |
2020 Aug 28 |
5 |
Technical information |
5 |
This animation describes the structure of coronaviruses like SARS-CoV-2 and how they infect humans and replicate inside cells. |
Structure of SARS-CoV-2 |
2021 Jan 22 |
| 25 |
3D Animation: How Do I Protect Myself From Coronavirus, COVID-19? |
Nucleus medical Media |
1min 33sec |
330457 |
4.9K |
299 |
2020 Apr 03 |
5 |
Very easy |
5 |
Public health advertisement |
Public health |
2021 Jan 22 |
| 26 |
How The Coronavirus Attacks Your Lungs |
Deep Look |
5mins 10sec |
431710 |
15K |
231 |
2020 May 05 |
5 |
Easy |
5 |
How lungs are affected by coronavirus |
Immunology |
2021 Jan 22 |
| 27 |
Explainer: How the coronavirus (SARS-CoV-2) infects human cells |
The Star |
2mins 08secs |
720536 |
3.9K |
221 |
2020 Mar 16 |
5 |
Technical information |
5 |
Animation how the virus affects the cells |
molecular biology |
2021 Jan 22 |
| 28 |
COVID-19 (SARS Coronavirus 2) - timeline, pathophysiology (ARDS), coronavirus life cycle, treatment |
Armando Hasudungan |
28mins 19secs |
266553 |
3.7K |
131 |
2020 Apr 07 |
5 |
Easy |
5 |
Timeline of Covid-19 pandemic |
Epidemiology |
2021 Jan 22 |
| 29 |
COVID-19 | Coronavirus: Epidemiology, Pathophysiology, Diagnostics |
Ninja Nerd Lectures |
58mins |
5.2million |
88K |
2.9K |
2020 Mar 17 |
5 |
Technical information |
5 |
lecture to understand the origin and zoonosis of COVID-19, the routes of transmission, epidemiology (current as of 3/15/2020), pathophysiology, and diagnostic tests used to identify COVID-19. |
Epidemiology, Pathophysiology, Diagnostics |
2021 Jan 22 |
| 30 |
COVID-19 | Coronavirus: How is Coronavirus Diagnosed | |
Ninja Nerd Lectures |
41mins 59secs |
124481 |
3.5K |
54 |
2020 Apr 21 |
5 |
Technical information |
5 |
Detail on the diagnostics used to diagnose COVID-19. |
Diagnostics |
2021 Jan 22 |
| 31 |
The origins of SARS-CoV-2 |
American Society for Microbiology |
2mins 51secs |
2561 |
25 |
9 |
2020 Sep 24 |
5 |
Technical information |
5 |
Origins of SARS-CoV-2 |
Moelcular biology |
2021 Jan 22 |
| 32 |
Introduction to Coronaviruses (SARS, MERS, COVID-19): Hosts, Symptoms, History of SARS and MERS |
JJ Medicine |
7mins 20secs |
264782 |
3.5K |
145 |
2020 Feb 02 |
5 |
Easy |
5 |
Hosts, Symptoms, History of SARS-CoV-2, SARS and MERS |
molecular biology |
2021 Jan 22 |
| 33 |
Coronavirus outbreak (covid 19) explained through 3D Medical Animation |
Scientific Animations |
6mins 08secs |
7545329 |
62k |
2.7K |
2020 Feb 11 |
5 |
Easy |
4 |
Coronavirus outbreak -Statistics |
Pandemic outbreak |
2021 Jan 22 |
| 34 |
Covid vaccines what do we need to know |
WHO |
53secs |
733K |
- |
- |
2021 Jan 22 |
5 |
Easy |
5 |
Is it ok to mix and match COVID-19 vaccines between the first dose and the second one? |
Vaccines |
2021 Jan 23 |
| 35 |
Q&A on COVID-19 with Dr Soumya Swaminathan and Dr Maria Van Kerkhove |
WHO |
53mins 21 sec |
512K |
- |
- |
2020 Oct 14 |
5 |
Technical information |
5 |
Q&A on COVID-19 with Dr Soumya Swaminathan and Dr Maria Van Kerkhove |
Public health |
2021 Jan 23 |
| 36 |
Tools to fight COVID-19 |
WHO |
1min 10sec |
347K |
- |
- |
2020 Dec 26 |
4 |
Easy |
5 |
Tools to fight COVID-19: Be your own superhero! We are in this together! |
Public health |
2021 Jan 23 |
| 37 |
Q&A on the new #COVID19 virus variant |
WHO |
40mins 36secs |
822K |
13K |
4.5K |
2020 Dec 23 |
5 |
Technical information |
5 |
Q&A on the new COVID-19 virus variant with WHO, COVID Genomic UK, and Sanger Institute's experts |
Public health |
2021 Jan 23 |
| 38 |
Three factors help you make safer choices when you are in Covid effected area |
WHO |
1min |
2.7K |
- |
- |
2021 Jan 23 |
5 |
Easy |
5 |
Animation: see how location, proximity and time can help you make safer choices when you're in an area of widespread COVID-19 transmission |
Public health |
2021 Jan 23 |
| 39 |
Coronavirus spike proteins |
Thermo Scientific EM & Spectroscopy |
1min 15sec |
34995 |
255 |
20 |
2017 Nov 17 |
3 |
Easy |
5 |
Cryo-electron microscopy (cryo-EM) is helping researchers determine the structure of coronavirus spike proteins-fueling strategies to prevent infections. |
Advertisement by Thermo Scientific |
2021 Jan 23 |
| 40 |
SARS-CoV-2 Structure (COVID-19 Coronavirus) |
Molecular Memory |
11mins 59 sec |
186375 |
4.7K |
96 |
2020 Apr 03 |
5 |
Technical information |
5 |
A structural exploration of the proteins produced by SARS-CoV-2. |
Virus structure |
2021 Jan 23 |
| 41 |
How COVID-19 Affects the Body |
Nucleus Medical Media |
4mins 02sec |
574562 |
10K |
343 |
2020 Jun 13 |
5 |
Technical information |
5 |
Animation showing how SARS-CoV-2 affects the body |
Public health |
2021 Jan 23 |
| 42 |
Model of Membrane Fusion by SARS CoV-2 Spike Protein |
ClarafiSciViz |
42secs |
10471 |
- |
- |
2020 Jun 21 |
5 |
Technical information |
5 |
A dynamic simulation and visual model of how the SARS CoV-2 Spike protein drives fusion of viral and cell membranes. |
molecular biology |
2021 Jan 23 |
| 43 |
What Happens If You Get a Severe Case of COVID-19? |
Nucleus Medical Media |
10mins 02sec |
1052182 |
14K |
691 |
2020 May 06 |
5 |
Easy |
5 |
What can happen to a healthy person in the unlikely event they develop a severe case of COVID-19 due to coronavirus. |
Public health |
2021 Jan 23 |
| 44 |
Computer modelling generating accurate simulation of COVID-19 spike protein |
CSIRO's Data61 |
36sec |
1522 |
16 |
1 |
2020 Apr 16 |
5 |
Technical information |
5 |
Accurate replica of COVID-19 to identify the regions of its proteins that could be good targets for a successful drug and minimise costly and time intensive lab testingA |
molecular biology |
2021 Jan 23 |
| 45 |
Understanding COVID-19 transmission, informing control |
OxfordSparks |
2mins 31 sec |
8147 |
36 |
1 |
2020 Aug 06 |
3 |
Technical information |
5 |
Tackling a previously unseen pathogen - like the one that causes COVID-19 - is like piecing together a puzzle. There are many different parameters to investigate before the pathogen can be fully understood, and before effective control measures can be put in place. So how do scientists go about solving the puzzle, and why is modelling so important? |
Scientific and Modelling analysis |
2021 Jan 23 |
| 46 |
Tracing the origins of SARS-CoV-2 animation |
RAZOR |
6mins 28secs |
- |
- |
- |
2020 Jun 07 |
5 |
Easy |
5 |
Since the beginning of the pandemic, researchers from around the world have attempted to use it to confirm the origins of SARS-CoV-2, the novel virus that causes COVID-19. In this RAZOR animation we explore the roots of a phylogenetic tree of coronaviruses to ask - where did SARS-CoV-2 come from? |
molecular biology |
2021 Jan 23 |
| 47 |
Understanding the Virus that Causes COVID-19 |
Alila Medical Media |
4mins 35secs |
595853 |
4K |
244 |
2020 Mar 28 |
5 |
Easy |
5 |
Overview of coronavirus family, origin of SARS-CoV-2, viral structure and life cycle, pathophysiology. |
Structure of SARS-CoV-2 |
2021 Jan 23 |
| 48 |
The Coronavirus Explained & What You Should Do |
Kurzgesagt - In a Nutshell |
8mins 34secs |
28755547 |
944K |
13K |
2020 Mar 19 |
5 |
Easy |
5 |
General explaination of |
|
1899 Dec 30 |
| 49 |
COVID-19 (Pregnancy & labor management) webinar by AIIMS, New Delhi |
AIIMS Telemedicine |
55mins 15secs67098 |
|
794 |
36 |
2020 Apr 09 |
5 |
Medium |
5 |
Webinar on Covid-19 : Pregrancy and labour management by SET facility , AIIMS, New Delhi |
Public health |
2021 Jan 29 |
| 50 |
Rapid Setting up of ICU AIIMS COVID-19 Webinar Series |
AIIMS Telemedicine |
34mins 38secs |
3023 |
72 |
1 |
2020 Apr 08 |
5 |
Technical information |
5 |
Webinar on Covid-19 by Prof.Anjan Trikha |
Public health |
2021 Jan 29 |
| 51 |
PPE Use in Different Areas of the Hospital |
AIIMS, New Delhi |
7mins 51sec |
4513 |
127 |
2 |
2020 Apr 08 |
5 |
Technical information |
5 |
Talk by Dr.Randeep Gularia, Director, AIIMS |
Hospital management |
2021 Jan 29 |
| 52 |
Using Personal Protection N95 Masks given to Health Care Workers at AIIMS |
AIIMS, New Delhi |
2mins 47secs |
10207 |
127 |
3 |
2020 Apr 27 |
5 |
Easy |
5 |
The recommended methods for storing and reusing the five N95 masks that have been issued for "Personal Protection" by Health Care Workers in hospital setting |
Public health |
2021 Jan 29 |
| 53 |
Re-Use of N95 Mask -JIPMER |
JIPMER OFFICIAL VIDEO |
10mins 25secs |
16410 |
267 |
19 |
2020 May 30 |
5 |
Easy |
5 |
Re-Use of N95 Mask -JIPMER |
Public health |
2021 Jan 29 |
| 54 |
COVID-19 Update 15: Can we disinfect and reuse N95 masks? |
Medmastery |
8mins 03secs |
447504 |
2.9K |
163 |
2020 Apr 07 |
5 |
Easy |
5 |
Personal protective equipment (including masks) are vital for protecting health care workers from infection with COVID-19. |
Public health |
2021 Jan 29 |
| 55 |
Biomedical Waste management, Disinfection & Cleaning in COVID-19 Areas |
AIIMS Telemedicine |
11mins 27 secs |
13464 |
187 |
3 |
2020 Apr 27 |
5 |
Technical information |
5 |
Biomedical waste management, Appropriate disinfection, Cleaning procedures. |
Public health |
2021 Jan 29 |
| 56 |
Hydroxychloroquine & COVID-19 |
AIIMS, New Delhi |
1min 55sec |
3280 |
106 |
2 |
2020 Apr 27 |
5 |
Easy |
5 |
Advice on use of Hydroxychloroquine by Dr.Randeep Gularia, Director, AIIMS |
Public health |
2021 Jan 29 |
| 57 |
COVID-19 Vaccines: MODERNA | PFIZER/BIONTECH | ASTRAZENECA |
Ninja Nerd Lectures |
43min 48sec |
439379 |
15K |
290 |
2020 Dec 07 |
5 |
Technical information |
5 |
Lecture discussing COVID-19 vaccines including Moderna, Pfizer/BioNTech, and Astrazeneca/Oxford. |
Vaccinology |
2021 Jan 29 |
| 58 |
Coronavirus and COVID-19 |
Doctor Klioze |
17min 04sec |
42965 |
970 |
20 |
2020 Apr 19 |
5 |
Easy |
5 |
Describes the physiology and potential treatment options of the SARS-CoV2 viral infection. |
Molecular biology |
2021 Jan 29 |
| 59 |
General Public: Care for Yourself |
Centers for Disease Control and Prevention (CDC) |
25secs |
4326 |
63 |
15 |
2021 Jan 02 |
5 |
Easy |
5 |
Tips to encourage taking care of yourself one small way each day. The COVID-19 pandemic may be stressful for people. Coping with stress in a healthy way will make you, the people you care about, and your community stronger. |
Public health |
2021 Jan 29 |
| 60 |
How to Clean and Disinfect Your Home if Someone has COVID-19 |
Centers for Disease Control and Prevention (CDC) |
2mins 03secs |
244939 |
1.5K |
102 |
2020 Aug 24 |
5 |
Easy |
5 |
Follow these tips for cleaning and disinfecting your home |
Public health |
2021 Jan 29 |
| 61 |
CDC COVID-19 Prevention Messages for Front Line Long-Term Care Staff: PPE Lessons |
Centers for Disease Control and Prevention (CDC) |
12mins 01sec |
348046 |
796 |
88 |
2020 Apr 27 |
5 |
Easy |
5 |
Learn what personal protective equipment (PPE) should be used in Long-Term Care facilities and Nursing Homes, when, and how to use it correctly to help protect yourself and residents from COVID-19. |
Public health |
2021 Jan 29 |
| 62 |
COVID-19: Questions and Answers |
Centers for Disease Control and Prevention (CDC) |
10mins 53secs |
19781 |
169 |
32 |
2020 Nov 20 |
5 |
Technical information |
5 |
CDC's Dr. Henry Walke answers common questions about COVID-19. |
Public health |
2021 Jan 29 |
| 63 |
Healthy Workplaces - Tips and Tools for Operating your Business |
Centers for Disease Control and Prevention (CDC) |
1hr 20secs |
1111 |
7 |
1 |
2020 Nov 21 |
5 |
Technical information |
5 |
Dr. McDonald shared updates on CDC's COVID-19 response, including the latest scientific information and what everyone should know about protecting themselves and others |
Public health |
2021 Jan 29 |
| 64 |
What to Expect After Getting a COVID-19 Vaccine |
Centers for Disease Control and Prevention (CDC) |
1min 27secs |
67616 |
323 |
388 |
2020 Dec 18 |
5 |
Easy |
5 |
After getting a #COVID19 vaccine, you may have some side effects, which are normal signs that your body is building protection against COVID-19. Call your healthcare provider if redness or tenderness increases after 24 hours, if your side effects are worrying you, or if they do not seem to be going away after a few days. |
Public health |
2021 Jan 29 |
| 65 |
What Clinicians Need to Know About Pfizer-BioNTech and Moderna Vaccines |
Centers for Disease Control and Prevention (CDC) |
59mins 22secs |
7578 |
98 |
16 |
2020 Dec 21 |
5 |
Technical information |
5 |
This video (COCA Call) will give clinicians an overview of the Pfizer-BioNTech and Moderna COVID-19 vaccines. Clinicians will learn about vaccine characteristics and administration, vaccinating special populations, and contraindications. They will also get answers to a number of clinical questions CDC has received about these new vaccines. |
Medicine |
2021 Jan 29 |
| 66 |
Religious Leaders and Prevention |
Centers for Disease Control and Prevention (CDC) |
2mins 41secs |
353 |
1 |
1 |
2020 Dec 31 |
5 |
Easy |
5 |
Global faith leaders can encourage everyone in the community to practice prevention strategies that help reduce the spread of COVID-19 |
Public health |
2021 Jan 29 |
| 67 |
What Your Test Results Mean |
Centers for Disease Control and Prevention (CDC) |
44secs |
4383 |
32 |
14 |
2020 Oct 28 |
5 |
Easy |
5 |
Actions to take to protect yourself and others when you receive either a negative or a positive COVID-19 test result. |
Public health |
2021 Jan 29 |
| 68 |
Do it for Yourself and Your Friends |
Centers for Disease Control and Prevention (CDC) |
31secs |
3179 |
44 |
13 |
2020 Oct 29 |
5 |
Easy |
5 |
Tips for preventing the spread of COVID-19 to you and your friends. |
Public health |
2021 Jan 29 |
| 69 |
Help Protect Yourself and Others |
Centers for Disease Control and Prevention (CDC) |
47secs |
7503 |
75 |
46 |
2020 Oct 30 |
5 |
Easy |
5 |
Help Protect Yourself and Others from COVID-19 |
Public health |
2021 Jan 29 |
| 70 |
Lecture 1: "COVID-19 and the pandemic" |
MIT Department of Biology |
56min 10secs |
45631 |
- |
- |
2020 Sep 04 |
5 |
Technical information |
5 |
The first lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Dr. Bruce Walker,eminent immunologist. founding directior of the Ragon Institute of MGH, MIT and Harvard gave a talk titled "Evolution of Covid-19 Pandemic: learning from the patients." |
Immunology, Epidemiology |
2021 Jan 29 |
| 71 |
Lecture 2: "Coronavirus biology" |
MIT Department of Biology |
56mins 08sec |
28620 |
- |
- |
2020 Sep 10 |
5 |
Technical information |
5 |
The second lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Britt Glaunsinger of the University of California, Berkeley gave a talk titled "Coronavirus biology." |
Molecular biology |
2021 Jan 29 |
| 72 |
Lecture 3: "Virology and lessons from the AIDS pandemic" |
MIT Department of Biology |
56mins 45sec |
12239 |
- |
- |
2020 Sep 16 |
5 |
Technical information |
5 |
The third lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. David Baltimore of Caltech gave a talk titled "Virology and lessons from the AIDS pandemic." |
Epidemiology |
2021 Jan 29 |
| 73 |
Lecture 4: "Insights from the COVID-19 pandemic" |
MIT Department of Biology |
48mis 47secs |
94940 |
- |
- |
2020 Sep 25 |
5 |
Technical information |
5 |
The fourth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), gave a talk titled "Insights from the COVID-19 pandemic." |
Public health |
2021 Jan 29 |
| 74 |
Lecture 5: "Viral immunology" |
MIT Department of Biology |
56mins 38secs |
14376 |
- |
- |
2020 Oct 03 |
5 |
Technical information |
5 |
The fifth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Michel Nussenzweig of The Rockefeller University gave a talk titled "Viral immunology." |
Immunology |
2021 Jan 29 |
| 75 |
Lecture 6: "Target cells and the innate response" |
MIT Department of Biology |
54mins 21secs |
11608 |
- |
- |
2020 Oct 13 |
5 |
Technical information |
5 |
The sixth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Shiv Pillai of the Ragon Institute and MGH gave a talk titled "Target cells and the innate response." |
Immunology |
2021 Jan 29 |
| 76 |
Lecture 7: "The patient" |
MIT Department of Biology |
57mins 06sec |
7458 |
- |
- |
2020 Oct 22 |
5 |
Technical information |
5 |
The seventh lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Victoria Clark of Whitehead Institute and MGH gave a talk titled "The patient." |
|
2021 Jan 29 |
| 77 |
Lecture 8: "Epidemiology" |
MIT Department of Biology |
55mis 49sec |
10092 |
- |
- |
2020 Oct 30 |
5 |
Technical information |
5 |
The eighth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Michael Mina of the Harvard T. H. Chan School of Public Health gave a talk titled "Epidemiology." |
Epidemiology |
2021 Jan 29 |
| 78 |
Lecture 9: "Immunology: T cells" |
MIT Department of Biology |
57mins 01secs |
8098 |
- |
- |
2020 Nov 06 |
5 |
Technical information |
5 |
The ninth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Arlene Sharpe of Harvard Medical School gave a talk titled "Immunology: T cells." |
Immunology |
2021 Jan 29 |
| 79 |
Lecture 10: "Vaccines" |
MIT Department of Biology |
56mins |
18116 |
- |
- |
2020 Nov 15 |
5 |
Technical information |
5 |
The tenth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Kizzmekia Corbett of the National Institutes of Health gave a talk titled "Vaccines." |
Vaccinology, Immunology |
2021 Jan 29 |
| 80 |
Lecture 11: "Immunology: antibodies" |
MIT Department of Biology |
53 mins |
26645 |
- |
- |
2020 Nov 19 |
5 |
Technical information |
5 |
The eleventh lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Akiko Iwasaki of Yale Medical School gave a talk titled "Immunology: antibodies." |
Immunology |
2021 Jan 29 |
| 81 |
Lecture 12: "Small molecule therapeutics" |
MIT Department of Biology |
56mins 54secs |
5453 |
- |
- |
2020 Nov 27 |
5 |
Technical information |
5 |
The twelfth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. James Bradner of Novartis Institutes gave a talk titled "Small molecule therapeutics." |
Vaccinology, Immunology |
2021 Jan 29 |
| 82 |
Lecture 13: "Therapeutics discovery" |
MIT Department of Biology |
1hr 02min 06sec |
4555 |
- |
- |
2020 Dec 03 |
5 |
Technical information |
5 |
The thirteenth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Skip Virgin of Vir Biotechnology gave a talk titled "Therapeutics discovery." |
Vaccinology, Immunology, Therapeutics |
2021 Jan 29 |
| 83 |
Lecture 14: "Rapid research response in a pandemic" |
MIT Department of Biology |
56mins 21 secs |
3628 |
- |
- |
2020 Dec 10 |
5 |
Technical information |
5 |
The fourteenth lecture in the COVID-19, SARS-CoV-2 and the Pandemic Series, presented by the MIT Department of Biology. Dr. Eric Lander of Broad Institute gave a talk titled "Rapid research response in a pandemic." |
Diagnostics |
2021 Jan 29 |
| 84 |
Distinguished Speaker: Covid-19 Vaccine, from discovery to delivery |
JHUCareyBusiness |
1hr 27mins |
35 |
- |
- |
2021 Jan 27 |
5 |
Technical information |
5 |
The development and deployment of an effective vaccine for COVID-19 could be the turning point in the fight against the deadly pandemic. A distinguished panel of public health experts and vaccine industry executives for an engaging discussion examining every aspect of the COVID-19 vaccine from discovery to manufacturing to delivery. |
Business, Economics, Vaccines |
2021 Jan 29 |
| 85 |
Coronaviruses 101: Focus on Molecular Virology |
Innovative Genomics Institute - IGI |
1hr 02 secs |
361516 |
7.6K |
171 |
2020 Mar 25 |
5 |
Technical information |
5 |
UC Berkeley professor and IGI Investigator Britt Glaunsinger, PhD, explains the evolution, genetics, and virulence of coronaviruses. |
Microbiology |
2021 Jan 29 |
| 86 |
COVID Catalysts | The biotechnology revolution delivering a greener and cleaner future |
The University of Manchester |
6mins 25sec |
194 |
5 |
- |
2020 Oct 16 |
5 |
Technical information |
5 |
Robert Field, Professor of Chemistry talks how Biotechnology promises a revolution in the way we make our future medicines, materials and fuels. |
Careers |
2021 Jan 29 |
| 87 |
Dr. Kizzmekia Corbett: Everything You Should Know About the COVID-19 Vaccines |
Urban Health Institute and Johns Hopkins Office of Diversity, Inclusion, and Health Equity |
1hr 32mins |
- |
- |
- |
2021 Jan 27 |
5 |
Technical information |
5 |
Webinar on Covid-19 vaccines by Dr. Kizzmekia Corbett- Scientific team: Coronavirus Vaccine team , NIH, NIAID, Vaccine reasearch centre |
Vaccinology, Community medicine |
2021 Jan 29 |
| 88 |
Coronavirus Update With Peter Piot, MD, PhD - Director of The London School of Hygiene and Tropical Medicine |
JAMA Network |
47mins 53secs |
4122 |
1981 |
5 |
2021 Jan 28 |
5 |
Technical information |
5 |
JAMA's Q&A series to discuss the global public health response to COVID-19 past, present, and future. |
Epidemiology, Expert talk |
2021 Jan 29 |
| 89 |
Preserving the Scientific Integrity of Getting to COVID-19 Vaccines : From Clinical Trials to Public Allocation |
Johns Hopkins University |
2hrs 55mis |
8301 |
- |
- |
2020 Oct 07 |
5 |
Technical information |
5 |
Johns Hopkins University and the University of Washington are bringing together leading experts to explore these issues and put forward a concise plan for protecting the scientific integrity of these lifesaving efforts. |
Expert talk |
2021 Jan 29 |
| 90 |
Part 2: Protecting Scientific Integrity in the Design & Conduct of COVID-19 Vaccine Efficacy Trials |
Johns Hopkins University |
40mins 44 secs |
549 |
- |
- |
2020 Oct 09 |
5 |
Technical information |
5 |
Protecting Scientific Integrity in the Design & Conduct of COVID-19 Vaccine Efficacy Trials : Design, execution and analysis of ongoing and planned COVID-19 vaccine trails |
Expert talk |
2021 Jan 29 |
| 91 |
ASL: I wear a mask because |
Centers for Disease Control and Prevention (CDC) |
30secs |
542 |
4 |
6 |
2020 Oct 30 |
5 |
Easy |
5 |
Why do we wear a mask? - with ASL |
Public health advetisement |
2021 Jan 29 |
| 92 |
3D Annimation: SARS-CoV-2 virus transmission leading to COVID -19 |
Nucleus Medical Media |
1min,31 sec |
18 lakh |
15K |
964 |
2020 Apr 01 |
5 |
Easy |
5 |
Virus transmission |
Transmission |
2021 Jan 30 |
| 93 |
Structure of Coronavirus with classification of viruses |
Physiology Open |
5 mins 51 secs |
18K |
427 |
12 |
2020 Mar 28 |
5 |
Easy |
5 |
General virus, contents, types and the corona virus |
Corona virus types |
2021 Jan 30 |
| 94 |
Coronavirus Update 59: Dr. Roger Seheult's Daily Regimen (Vitamin D, C, Zinc, Quercetin, NAC |
MedCram |
18 mins 32 secs |
584K |
14K |
296 |
2020 Apr 22 |
5 |
Easy |
5 |
Information, with research evidence, on signficance of vitamins and other nutrition-supplements, tips for health professionals who fight Covid-19; |
Vitamins & Covid-19 |
2021 Jan 30 |
| 95 |
How Coronavirus Kills: Acute Respiratory Distress Syndrome (ARDS) & COVID 19 Treatment |
MedCram |
11 mins 04 sec |
4016K |
56K |
1.8K |
2020 Jan 29 |
5 |
Easy |
5 |
Brief & clear explanation of what happens to patients in severe cases, and description of modification of ventilation procedures, with references that provided evidences |
Patient care |
2021 Jan 30 |
| 96 |
Astrazeneca : Biomanufacturing a COVID-19 vector vaccine |
Astrazeneca |
2mins 12 secs |
- |
- |
- |
2020 Oct 01 |
5 |
Easy |
5 |
Animation of biomanufacturing a COVID-19 vector vaccine |
Bioengineering, Vaccines |
2021 Jan 29 |
| 97 |
COVID-19 vaccine from any country will work in India: CCMB |
TNIE Videos |
1mins 40secs |
1084 |
8 |
1 |
2020 Sep 20 |
5 |
Easy |
5 |
News bit from the New Indian Express and CCMB |
News Video |
2021 Jan 29 |
| 98 |
New variant causes more symptoms |
Dr. John Campbell |
30mins 52 secs |
240323 |
8.6K |
308 |
2021 Jan 28 |
5 |
Technical information |
5 |
Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19 in England |
Symptoms |
2021 Feb 01 |
| 99 |
Covid-19: Vaccine Roll-out, the State of the Pandemic, and Variants -- in the U.S. and U.K. |
UCSF School of Medicine |
1hr 19mins |
7157 |
- |
- |
2021 Jan 29 |
5 |
Technical information |
5 |
In this UCSF Department of Medicine Covid Grand Rounds, Susan Philip, the acting Health Officer for the SF Department of Public Health, will give us an update on vaccine distribution in San Francisco. Exploring the new viral variants from two perspectives. Shane Crotty, Professor of Immunology at the La Jolla Institute, will describe our evolving understanding of all of the variants, what they mean for California and the U.S., and how we should respond. Sir Patrick Vallance, Chief Scientific Adviser for the United Kingdom, will discuss the UK's experience with the B117 variant, including emerging information that the variant may not only be more infectious but potentially more likely to be fatal too. |
Immunology, Epidemiology |
2021 Feb 01 |
| 100 |
What you need to know about spring allergies and COVID-19 |
Mayo Clinic |
3mins 24secs |
21780 |
96 |
13 |
2020 Apr 03 |
5 |
Easy |
5 |
with the arrival of spring comes an increase in seasonal allergies and now questions about increased risk related to COVID-19. "Currently, there is no data to substantiate those patients with allergies and asthma are at an increased risk for COVID-19. And there's nothing in the literature to suggest that COVID-19 affects these people differently," says Dr. Arveen Bhasin, a Mayo Clinic allergy and immunology specialist. |
Symptoms |
2021 Feb 01 |
| 101 |
Home Care Tips For Mild COVID-19 Cases by Dr. Sushila Kataria |
Medanta |
7mins 17secs |
1631107 |
34K |
780 |
2020 Jul 20 |
5 |
Easy |
5 |
Dr. Sushila Kataria, Senior Director, Internal Medicine, Medanta Gurugram shares home care tips for patients with mild COVID-19 symptoms, who have been advised home isolation by their doctors. |
Public health |
2021 Feb 01 |
| 102 |
How does COVID-19 affect the heart? |
Mayo Clinic |
4mins 48secs |
48441 |
482 |
22 |
2020 Apr 03 |
5 |
Easy |
5 |
The effects of COVID-19 on the lungs are well-known. As the COVID-19 pandemic continues, more information is becoming available about the role the virus, called SARS-CoV-2, has on the heart. "Individuals with known cardiovascular disease are at an increased risk of more severe complications from respiratory viral illnesses, including the flu and COVID-19," says Dr. Leslie Cooper, chair of the Department of Cardiology at Mayo Clinic. |
Symptoms |
2021 Feb 01 |
| 103 |
The Effects of COVID-19 on the Heart: Patient Andre Taylor's story |
MedStar Washington Hospital Center |
3mins 41secs |
684 |
8 |
0 |
2020 Oct 15 |
5 |
Easy |
5 |
Patient André Taylor beat coronavirus, but he developed abnormal heart rhythms, likely from his bout with COVID-19. Dr. Cyrus Hadadi of MedStar Washington Hospital Center tell Washington why some COVID-19 patients show signs of heart damage, even weeks or months after feeling better. |
Medicine |
2021 Feb 01 |
| 104 |
Heart Muscle Damage from COVID-19 |
GIBLIB |
8mins 56secs |
17250 |
139 |
9 |
2020 Sep 01 |
5 |
Easy |
5 |
From the beginning of the COVID-19 pandemic, it was that known the disease affected the lungs. But some of the most severe damage to the body can be to the heart muscle. COVID-related myocarditis, or inflammation of the heart muscle, can cause severe damage and sometimes death. Mayo Clinic Q&A podcast, Dr. Leslie Cooper, chair of Cardiology at Mayo Clinic in Florida, discusses how COVID-19 affects the heart in hospitalized patients, in young people and he identifies areas of research that need to be pursued in the near future. |
Medicine |
2021 Feb 01 |
| 105 |
How to diagnose POST COVID 19 chest pain crowing rooster maneuver |
Dr KK Aggarwal |
2mins 44secs |
54148 |
1.1K |
26 |
2020 Aug 10 |
4 |
Easy |
5 |
Difference between heart pain and Costo chondritis |
Medicine |
2021 Feb 01 |
| 106 |
Covid 19 - Home Exercises Program to improve Lung capacity |
Dr.Smita Ingle |
29mins 38secs |
738277 |
10K |
414 |
2020 Mar 31 |
5 |
Easy |
5 |
Exercises to Improve your Lung capacity |
Public health |
2021 Feb 01 |
| 107 |
How coronavirus antibody tests work and why they matter | COVID-19 Special |
DW News |
12mins 45secs |
83275 |
887 |
55 |
2020 Apr 14 |
3 |
Easy |
5 |
Antibodies are also used in vaccines to make people immune to future infections. But immunity doesn't last a lifetime in all cases. So what do we know about Sars-CoV-2? How long will people be immune after an infection? |
Epidemiology, News video |
2021 Feb 01 |
| 108 |
Oxford University's 'vaccine for the world' is effective |
University of Oxford |
47secs |
16944 |
369 |
12 |
2020 Nov 23 |
5 |
Easy |
5 |
The interim phase III trial results are in: Oxford University's COVID-19 vaccine is effective. |
Vaccine |
2021 Feb 01 |
| 109 |
Covishield Vaccine: All You Need to Know |
NDTV |
1mins 51secs |
7426 |
77 |
9 |
2021 Jan 02 |
5 |
Easy |
5 |
The Oxford-AstraZenenca covid-19 vaccine - being developed by Serum Institute - will be called 'COVISHIELD'. Partial results from studies that saw participation of about 24,000 people in Britain, Brazil and South Africa suggest the AstraZeneca shots are safe and about 70 per cent effective in preventing coronavirus infection. The vaccine is expected to be used in many countries because of its low cost and the fact that it can be kept in refrigerators instead of the ultra-cold or freezer temperatures. The vaccine can be stored at 2-8 Degrees for at least six months. |
Vaccine, News video |
2021 Feb 01 |
| 110 |
Frequently asked Queries about Indian Covid Vaccines COVISHIELD and COVAXIN (HINDI) |
Dr. Sparsh Gupta - Pathology |
7mins 51 secs |
42276 |
3K |
36 |
2021 Jan 24 |
5 |
Easy |
5 |
This is an educational video based on the Guidelines issued by the Government of India. |
Vaccine |
2021 Feb 01 |
| 111 |
India's COVAXIN vs American COVID Vaccines | Cheaper , Better ? (Hindi) |
Gareeb Scientist |
14mins 05secs |
347749 |
12K |
395 |
2020 Dec 08 |
5 |
Easy |
4 |
India's Bharat Biotech is developing COVAXIN, how is different from foreign american vaccines? we will compare the differences. |
Vaccine |
2021 Feb 01 |
| 112 |
Testing face masks: Lab tests reveal the safest and most effective (Marketplace) |
CBC News |
7mins 41secs |
891240 |
11K |
844 |
2020 Nov 14 |
5 |
Easy |
5 |
How effective are your face masks? Months into the coronavirus pandemic there are still no standards or regulations for consumer masks. So we asked the University of Toronto to test more than 20 different masks. We reveal which are the most effective at keeping you safe from COVID-19, and which masks you should avoid. |
Public health |
2021 Feb 01 |
| 113 |
What to expect if you're diagnosed with COVID-19 |
UCLA Health |
8mins 24secs |
10741 |
216 |
12 |
2020 Dec 16 |
5 |
Easy |
5 |
If you are diagnosed with COVID-19, please keep in mind that most people do very well and are able to take care of themselves at home, without ever being hospitalized. This video includes information on how to isolate and care for yourself at home, and what to do if you experience troubling symptoms. |
Public health |
2021 Feb 02 |
| 114 |
COVID-19: The Science of How we Got Here and Where we are Headed |
University of California Television (UCTV) |
1hr 28mins |
3155 |
118 |
10 |
2020 Nov 23 |
5 |
Technical information |
5 |
Dr. George Rutherford, a professor of epidemiology and biostatistics at UCSF, explores what we know about SARS-CoV-2, the virus that causes COVID-19, and what the future holds. He talks about intervention, vaccines and models of super spreading. |
Epidemiology |
2021 Feb 02 |
| 115 |
Aerosolized Nanobodies for SARS-COV-2 Passive Immunization |
University of California Television (UCTV) |
1hr 25mins |
3012 |
110 |
7 |
2020 Oct 31 |
5 |
Technical information |
5 |
As the world awaits vaccines to bring the COVID-19 pandemic under control, UC San Francisco scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease. They are focused on the potential of virus-neutralizing monoclonal antibodies (mAbs) to treat COVID-19 by passive immunization. |
Therapeutics |
2021 Feb 02 |
| 116 |
Is COVID-19 a Heart Disease? |
University of California Television (UCTV) |
1hr 17mins |
6850 |
182 |
7 |
2020 Nov 21 |
5 |
Technical information |
5 |
COVID-19 was initially identified as a respiratory disease, but scientists now know that it also affects several other organs in the body, including the heart. Heart damage is a major determinant of COVID-19 related deaths, and even patients who experience only mild COVID-19 symptoms exhibit signs of cardiac dysfunction after recovery. UCSF researchers Todd McDevitt and Bruce Conklin explore how SARS-CoV-2, the virus that causes COVID-19, inflicts damage on heart cells. |
Medicine |
2021 Feb 02 |
| 117 |
Diagnosing and Tracking COVID-19 |
University of California Television (UCTV) |
57mins 11secs |
3352 |
80 |
9 |
2020 Jun 13 |
5 |
Technical information |
5 |
Dr. Chaz Langelier, UCSF Infectious Disease experts, talks about the importance of widespread testing for a disease that spreads through asymptotic or pre-symptomatic individuals. He also talks about lower respiratory tract infections (LRTI), the leading cause of death due to infection. C |
Diagnostics |
2021 Feb 02 |
| 118 |
Targeting COVID-19 Viral Enzymes |
University of California Television (UCTV) |
1hr 06mins |
1633 |
61 |
5 |
2020 Dec 06 |
5 |
Technical information |
5 |
UCSF scientists studying a key enzyme used by the virus that causes COVID-19 have identified chemical building blocks that might eventually be used to make an antiviral drug. The chemical fragments could bind to and disable the enzyme, called the "macro domain," which is a crucial part of the SARS-CoV-2 virus's ability to replicate in human cells. James Fraser discusses the finding from this research. |
Structure, Molecular interactions |
2021 Feb 02 |
| 119 |
COVID-19 Testing, Surveillance, and Diagnosis: Notes from a Disease Detective |
University of California Television (UCTV) |
1hr 19mins |
2179 |
62 |
8 |
2020 Nov 07 |
5 |
Technical information |
5 |
Dr. Charles Chiu, UCSF Professor, Department of Laboratory Medicine and Medicine / Infectious Diseases, explores the various tests and their features. He also talks about SARS-CoV-2 genomic sequencing and its uses and a new study to identify biomarkers of the virus. |
Diagnostics |
2021 Feb 02 |
| 120 |
How vaccines work against COVID-19: Science, Simplified |
Scripps research |
2min16sec |
92k |
792 |
63 |
2020 Dec 18 |
5 |
Easy |
5 |
mRNA vaccines |
Vaccine |
2021 Feb 02 |
| 121 |
COVID-19 and Breastfeeding |
University of California Television (UCTV) |
1min 18sec |
2500 |
24 |
11 |
2020 Oct 28 |
5 |
Easy |
5 |
Can I breastfeed if I have COVID-19? Dr. Julia Cormano explains what you need to know to safely breastfeed if you are ill. |
Public health |
2021 Feb 02 |
| 122 |
Identifying the Peptides that Activate T Cells in COVID-19 Patients - Albert Wong |
University of California Television (UCTV) |
12mins 55secs |
1256 |
56 |
3 |
2020 Sep 25 |
5 |
Easy |
5 |
Identifying the Peptides that Activate T Cells in COVID-19 Patients |
Immunology |
2021 Feb 02 |
| 123 |
Coping with COVID-19: Mental Health Strategies - Health Talks |
University of California Television (UCTV) |
1hr |
1794 |
43 |
1 |
2020 Jun 27 |
5 |
Technical information |
5 |
Experts from the UC San Diego Department of Psychiatry talk about the impacts of COVID-19 on memtal health. They share tips for managing anxiety in children, the health consequences of negative experiences, suicide prevention, effective mental health treatments, treatment during the pandemic and much more. |
Public health |
2021 Feb 02 |
| 124 |
The COVID-19 Pandemic: Insights and Overview |
The Rockefeller University |
1hr 18mins |
395 |
11 |
1 |
2021 Jan 15 |
5 |
Technical information |
5 |
Neutralizing Antibodies: Precision-guided Weapons against SARS-CoV-2. Marina Caskey, M.D., professor of clinical investigation, Laboratory of Molecular Immunology at The Rockefeller University |
Immunology, Therapeutics |
2021 Feb 02 |
| 125 |
COVID-19 Testing and Biosafety Practices |
ICMR Organisation |
20mins 37secs |
3036 |
91 |
1 |
2020 Jun 16 |
3 |
Easy |
5 |
COVID-19 Testing and Biosafety Practices developed by ICMR- National Institute of Virology, Pune |
Testing and biosafety |
2021 Feb 02 |
| 126 |
Are COVID-19 vaccines safe for people with autoimmune diseases? |
WHO |
42secs |
125K |
- |
- |
2021 Jan 31 |
3 |
Easy |
5 |
Are COVID-19 vaccines safe for people with autoimmune diseases? |
Public health |
2021 Feb 02 |
| 127 |
We can outsmart the COVID-19 virus |
WHO |
55secs |
2.1million |
- |
- |
2021 Jan 29 |
3 |
Easy |
5 |
Be your own superhero: -clean your hands, open windows, wear a mask, keep physical distance, cough/sneeze in your elbow -Dr. Maria Van Kerhnove |
Public health |
2021 Feb 02 |
| 128 |
COVID-19 Vaccines: What Is An mRNA Vaccine? |
Vanderbilt Health |
1min 16secs |
2768 |
- |
- |
2020 Dec 15 |
4 |
Easy |
5 |
Covid-19 and vaccines |
Vaccines |
2021 Feb 02 |
| 129 |
COVID-19 Vaccine 101: Will a Vaccine Be Safe? |
Vanderbilt Health |
4mins 21secs |
1452 |
_ |
- |
2020 Dec 15 |
5 |
Easy |
5 |
Covid-19 and vaccines |
Vaccines |
2021 Feb 02 |
| 130 |
"Post-acute COVID-19 Syndrome": COVID "long-haulers" suffering symptoms months after initial diagnosis |
60minutes |
13mins |
1236959 |
19K |
1.1K |
2020 Nov 24 |
5 |
Easy |
5 |
Anderson Cooper reports how doctors are still searching for answers to why a portion of people who were diagnosed with COVID-19 are still suffering symptoms months later. |
Symptoms |
2021 Feb 07 |
| 131 |
Long Covid: When coronavirus symptoms don't go away |
DW News |
12mins 33secs |
252496 |
2.9K |
133 |
2020 Dec 13 |
5 |
Easy |
5 |
Many cases where patients develop mild symptoms that only last for a few weeks or show no symptoms at all. And then, there's long Covid. That's when patients still experience symptoms months after a Covid infection. There's still a lot that researchers don't understand about the novel coronavirus - and the same goes for long Covid. |
Symptoms |
2021 Feb 07 |
| 132 |
A Visual Guide to the New Coronavirus Variants |
Scientific American |
6mins 22secs |
5524 |
121 |
4 |
2021 Feb 11 |
5 |
Medium |
5 |
The more viruses that exist in the world, the greater the chance that one will evolve a dangerous mutation.In this video, we explain what the new variants actually are, how they arise and spread, and what they could mean for the future of our ability to vaccinate ourselves against the virus. |
Mutations |
2021 Feb 18 |
| 133 |
COVID-19: The New Variants | |
Al Jazeera English |
6mins 40secs |
80957 |
1.8K |
130 |
2021 Jan 18 |
5 |
Easy |
5 |
The virus that causes COVID-19 is mutating and spreading around the world. It's led to more contagious variants, including one that's caused an unprecedented spike in cases in the UK. Vaccine roll-outs are in full swing but will they still work? |
Mutations |
2021 Feb 18 |
| 134 |
The New Vaccines, Attitudes Toward Vaccination, and the Biden Covid-19 Task Force |
UCSF School of Medicine |
1hr 36mins |
13912 |
~ |
~ |
2021 Feb 12 |
5 |
Technical information |
5 |
n this UCSF Department of Medicine Covid Grand Rounds, we'll begin with a discussion of the new vaccine candidates. Just in the past few weeks, we've seen new data regarding several vaccines, including J&J, AstraZeneca, and Novavax. |
Vaccines |
2021 Feb 18 |
| 135 |
Understanding what's driving coronavirus mutations | COVID-19 Special |
DW News |
11mins 52sec |
175165 |
1.7K |
118 |
2021 Jan 29 |
5 |
Technical information |
5 |
New mutations have seen the virus spread like wildfire in parts of the world. Over a year after the virus was first reported, there are now a large number of strains. Some, like the variants detected in the UK and South Africa, seem to be spreading much faster. Each new infection opens the door to unknown variants which threaten to undo the progress that has been made in the fight against the pandemic. The big question is: will the existing vaccines still work? |
Vaccines, Mutations |
2021 Feb 18 |
| 136 |
How dangerous is South Africa's coronavirus variant? | COVID-19 Special |
DW News |
15mins 18secs |
145318 |
1.3K |
121 |
2021 Feb 08 |
5 |
Technical information |
5 |
South African scientists are downplaying the danger of a new Covid-19 variant identified in the country towards the end of 2020. Covid-19 501.V2 has been found in all of the country's nine provinces and has led to several countries banning flights from South Africa. The variant has been associated with a higher viral load, leading some scientists to believe it is more transmissible and possibly a major contributing factor in the surge in infections around the globe. However the government & leading scientists are blaming the current surge in infections to a lack of adherence to coronavirus containment measures and "superspreader" events during the festive period. |
Vaccines, Mutations |
2021 Feb 18 |
| 137 |
Life Cycle of the Coronavirus |
Johns Hopkins Bloomberg School of Public Health |
2mins 42 secs |
65601 |
217 |
18 |
2020 Jul 13 |
5 |
Easy |
5 |
How does SARS-CoV2 infect people, and what are researchers learning about its possible vulnerabilities? |
Molecular biology |
2021 Feb 20 |
| 138 |
Coronavirus Update With CDC Director Rochelle Walensky |
JAMA Network |
38mins 21secs |
13772 |
331 |
24 |
2021 Feb 18 |
5 |
Technical information |
5 |
Centers for Disease Control and Prevention (CDC) Director Rochelle P. Walensky, MD, MPH discusses the agency's response to emerging variants, implications for the planned vaccine mobilization strategy, the upcoming J&J vaccine FDA advisory hearings, strategies for reopening K-12 schools, and other agency activities and priorities related to COVID-19 control. |
Variants, Public health |
2021 Feb 20 |
| 139 |
Coronavirus mRNA Vaccine Safety and Efficacy |
JAMA Network |
9mins 36secs |
4035 |
|
|
2021 Feb 19 |
5 |
Easy |
5 |
Millions of people are now being immunized with mRNA vaccines from Pfizer-BioNTech and Moderna. Both vaccines have very high efficacy and look safe in the short-term. This video reviews experience with the vaccines since they were authorized for use in December 2020 |
Vaccines |
2021 Feb 20 |
| 140 |
Coronavirus Update With Anthony Fauci |
JAMA Network |
24mins |
38475 |
790 |
61 |
2021 Feb 04 |
5 |
Technical information |
5 |
Emerging genetic variants and implications for vaccine efficacy and prospects for new vaccine |
Vaccines, Variants |
2021 Feb 20 |
| 141 |
Coronavirus Variants - What They Mean |
JAMA Network |
36mins 08secs |
25764 |
580 |
20 |
2021 Feb 05 |
5 |
Technical information |
5 |
explain the variants and what they mean for public health. |
Vaccines, Variants |
2021 Feb 20 |
| 142 |
Coronavirus Vaccine Update With Paul Offit |
JAMA Network |
34mins 39secs |
29032 |
574 |
40 |
2021 Feb 12 |
5 |
Technical information |
5 |
Paul A. Offit, MD of the Children's Hospital of Philadelphia provides an update on the emergence of COVID-19 variants and their implications for vaccine development, including the JNJ vaccine, scheduled for a .S. Food and Drug Administration VRBPAC hearing on February 26, 2021. |
Vaccines, Variants |
2021 Feb 20 |
| 143 |
Coronavirus Vaccines - An Introduction |
JAMA Network |
9mins 53secs |
9740330 |
43K |
17K |
2020 Oct 02 |
5 |
Easy |
5 |
Leading COVID-19 vaccine candidates rely on new technologies that have fast-tracked development and testing. Vaccines from Pfizer and Moderna have completed early phase 3 clinical trials and are reportedly under review at the US FDA for emergency use authorization (EUA) although safety surveillance continues. This video explains the principles underlying the leading DNA, messenger RNA (mRNA), and viral vector vaccine candidates, and how they might induce immunity to SARS-CoV-2 infection. |
Vaccines |
2021 Feb 20 |
| 144 |
Coronavirus Treatment and Prevention With Monoclonal Antibodies |
JAMA Network |
5mins 55 secs |
301283 |
12K |
213 |
2020 Jul 01 |
5 |
Easy |
5 |
Neutralizing monoclonal antibodies (mAbs) may be a highly effective way to treat and prevent COVID-19 while waiting for a vaccine. Watch this video to find out how these drugs are created and how they target the SARS-CoV-2 virus. |
Medicine |
2021 Feb 20 |
| 145 |
COVID Vaccination in Pregnant and Breastfeeding Individuals |
JAMA Network |
41mins 58secs |
38571 |
|
|
2021 Feb 09 |
5 |
Technical information |
5 |
As U.S. vaccine distribution expands to include younger healthier populations, questions about vaccine safety in women of childbearing age have become more urgent. UTSWMed 's Catherine Y. Spong, MD and Emory Healthcare 's Denise J. Jamieson, MD, MPH, both eminent obstetrician/gynecologists, discuss the safety of the Pfizer/BioNTech and Moderna vaccination in pregnant and nursing moms, and in women trying to get pregnant. |
Vaccines |
2021 Feb 20 |
| 146 |
Zinc and Vitamin C for COVID-19 Symptoms |
JAMA Network |
24mins 19secs |
3828 |
123 |
13 |
2021 Feb 17 |
4 |
Technical information |
5 |
Milind Y. Desai, MD, MBA, discusses a randomized clinical trial examining whether high-dose zinc and/or high-dose ascorbic acid reduces the severity or duration of symptoms compared with usual care among ambulatory patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. |
Symptoms |
2021 Feb 20 |
| 147 |
The Science Behind Why New Covid Variants Are Spreading Faster |
Wall Street Journal |
7mins 01secs |
40716 |
727 |
226 |
2021 Feb 19 |
5 |
Technical information |
5 |
As highly transmissible coronavirus variants sweep across the world, scientists are racing to understand why these new versions of the virus are spreading faster, and what this could mean for vaccine efforts. New research says the key may be the spike protein, which gives the coronavirus its unmistakable shape. |
Variants, Public health |
2021 Feb 20 |
| 148 |
Herd Immunity as a Coronavirus Pandemic Strategy |
JAMA Network |
56mins 57secs |
44590 |
811 |
44 |
2020 Nov 07 |
5 |
Technical information |
5 |
Would letting coronavirus infect the broad US and global population be a safe and effective means of ending the COVID-19 pandemic? Jay Bhattacharya, MD, PhD, of Stanford University's Center for Primary Care and Outcomes Research is a signatory of the 'Great Barrington Declaration,' which proposes to "allow those at minimal risk of death to live their lives normally to build up immunity to the virus through natural infection, while better protecting those who are at highest risk." Marc Lipsitch, PhD, of the Harvard T.H. Chan School of Public Health, a signatory of the 'John Snow Memorandum' which refutes the argument, responds. |
Public health, Immunology, Ethics |
2021 Feb 20 |
| 149 |
SARS-CoV-2 Life Cycle |
RCSBProteinDataBank |
4mins 21secs |
11646 |
201 |
7 |
2020 Oct 01 |
5 |
Technical information |
5 |
Overview of SARS-CoV-2 life cycle |
Molecular biology |
2021 Feb 20 |
| 150 |
SARS-CoV-2 Evolution |
RCSBProteinDataBank |
1min 40secs |
1698 |
46 |
1 |
2020 Oct 01 |
5 |
Technical information |
5 |
This video discusses where the SARS-CoV-2 infection may have come from and how it has been evolving as it spreads around the world (between late 2019 and middle of 2020) |
Evolution |
2021 Feb 20 |
| 151 |
SARS-CoV-2 Main Protease |
RCSBProteinDataBank |
55secs |
1261 |
33 |
1 |
2020 Oct 01 |
5 |
Technical information |
5 |
This video showcases the overall structure of the SARS-CoV-2 Main Protease enzyme and discusses its and functi |
Structure, Molecular interactions |
2021 Feb 20 |
| 152 |
Developing SARS-CoV-2 Vaccines (2020) |
RCSBProteinDataBank |
14mins 53secs |
1668 |
38 |
0 |
2020 Oct 01 |
5 |
Medium |
5 |
This video describes the approaches that are being used to develop a SARS-CoV-2 vaccine, using knowledge accumulated from studying other coronaviruses. Short lecture by Dr. Lisa Denzin, Rutgers University. |
Vaccines |
2021 Feb 20 |
| 153 |
SARS-CoV-2 Variants | UK + South African + Brazil Variants |
Ninja Nerd Lectures |
42mins 59secs |
16738 |
1.7K |
3 |
2020 Feb 15 |
5 |
Technical information |
5 |
This video discusses discuss the three primary variants we are currently aware of. The first variant we discuss is the UK variant, also known as B.1.1.7. Next we discuss the South African variant, also known as B.1.351. Finally, we break down the science behind the Brazil variant, also known as P.1. |
Viral variants |
2021 Feb 20 |
| 154 |
The Spike story |
RCSBProteinDataBank |
1min 45secs |
1948 |
76 |
1 |
2020 Oct 01 |
5 |
Technical information |
5 |
This video illustrates the structures of the SARS-CoV-2 Spike protein and human ACE2 binding - a step that begins the infection. |
Structure |
2021 Feb 20 |
| 155 |
How coronaviruses get into cells |
Tom Goddard |
17mins 53secs |
34494 |
1.1K |
26 |
2020 Feb 04 |
5 |
Technical information |
5 |
Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 |
|
2021 Feb 20 |
| 156 |
Headache and COVID-19 |
IHS International Headache Society |
7mins 40secs |
28 |
4 |
|
2020 Nov 09 |
5 |
Technical information |
5 |
Covid -19 and headache related information |
Public health |
2021 Feb 21 |
| 157 |
New cornonavirus variants-Explained simply |
Genomics Gurus |
56mins 39secs |
6068 |
130 |
8 |
2021 Jan 08 |
5 |
Easy |
5 |
This video explains coronavirus variants, mutations, PCR tests in simple terms, so that you can make more sense of media reports and the changing restrictions to our daily lives. You will also learn some cool molecular biology! |
Molecular biology |
2021 Feb 24 |
| 158 |
Quick look at 3 new coonavirus variants |
Genomics Gurus |
8mins 04secs |
4967 |
116 |
4 |
2021 Jan 22 |
5 |
Easy |
5 |
A quick look at the three new coronavirus variants from the UK, South Africa and Brazil. This video summarises the SARS-CoV-2 mutations and what the main clinical features of these variants are. |
Variants |
2021 Feb 24 |
| 159 |
The spread of 3 new coronavirus variants - A close look at the scientific data |
Genomics Gurus |
1hr 05mins |
817 |
24 |
1 |
2021 Jan 20 |
5 |
Techincal information |
5 |
This presentation gathers together all the scientific data about the rapid spread of three new coronavirus variants that are changing how we need to manage the COVID-19 pandemic. |
Variants |
2021 Feb 24 |
| 160 |
Delivery strategies and infection prevention and IPC procedures for COVID-19 vaccination |
ProjectECHO |
1hr 29mins 30secs |
12 |
|
|
2021 Jan 26 |
5 |
Techincal information |
5 |
|
Vaccines |
2021 Feb 24 |
| 161 |
COVID, Thrombosis, and the Research: Steering into the Storm with Full Sails |
NAThrombosisForum |
1hr 31mins |
51 |
1 |
|
2021 Feb 19 |
5 |
Technical information |
5 |
This video addresses the unique cardiovascular (CV) risks and challenges that patients face when recovering from COVID-19, with a particular focus on thrombotic illnesses. The epidemiology, pathophysiology, and prevention of CV complications in COVID-19 was discussed, and the program concluded with a case series exploring key clinical dilemmas in COVID-19-associated thrombosis. |
Medicine, symptoms |
2021 Feb 24 |
| 162 |
Clot Chronicles: CORONA-VTE—Cardiovascular Findings in COVID-19 |
NAThrombosisForum |
7mins 53secs |
126 |
3 |
|
2020 Dec 01 |
5 |
Technical information |
5 |
Dr. Gregory Piazza, an Associate Professor of Medicine at Harvard Medical School as well as Staff Physician and Section Head of Vascular Medicine at Brigham and Women's Hospital, discusses CORONA-VTE. |
Medicine, symptoms |
2021 Feb 24 |
| 163 |
COVID-19 Associated Thrombosis: Who is at risk? |
Frederick Southwick |
12mins 02secs |
93 |
4 |
|
2020 Sep 05 |
5 |
Technical information |
5 |
Dr. Anita Rajasekhar, Associate Professor of Medicine at the University of Florida reviews the evidence for an increased predisposition to thrombosis in patients with COVID-19. The majority of events are venous thrombosis, but cases of limb ischemia and stroke, particularly in younger patients have bee reported. There is now agreement that SARS-CoV-2 infection is associated with an increased risk for thrombosis. |
Medicine, symptoms |
2021 Feb 24 |
| 164 |
COVID 19 and Coagulapathy: Observations, Prognosis, Monitoring and Interventions | Dr. Adam Cuker |
Penn Medicine |
16mins 05secs |
223 |
3 |
|
2020 Oct 03 |
5 |
Techincal information |
5 |
Dr. Adam Cuker talks about COVID 19 and Coagulapathy: Observations, Prognosis, Monitoring and Interventions |
Medicine, symptoms |
2021 Feb 24 |
| 165 |
COVID Vaccine FAQ - Penn Medicine Chief Medical Officer P.J. Brennan Answers Your Questions |
Penn Medicine |
9mins 13secs |
697 |
12 |
|
2021 Feb 12 |
5 |
Easy |
5 |
By the time the first COVID-19 Vaccinations were administered in December 2020, the virus had taken the lives of over 300,000 people in the United States. P.J. Brennan, MD, Chief Medical Officer of the University of Pennsylvania Health System answers the most frequently asked questions about the COVID-19 vaccine, and explains why it is important for everyone to get their shot. |
Vaccines, Public health |
2021 Feb 24 |
| 166 |
Laying the Groundwork for COVID-19 Vaccines: Dr. Drew Weissman and mRNA Technology at Penn Medicine |
Penn Medicine |
2mins 45secs |
5103 |
51 |
7 |
2021 Jan 05 |
5 |
Easy |
5 |
Dr. Drew Weissman talks on the development of mRNA technology and how years of research led to the development of COVID-19 vaccines, as well as promising new vaccines for influenza, herpes, HIV, and many other diseases. |
Vaccines |
2021 Feb 24 |
| 167 |
COVID Vaccine and Pregnancy: A Town Hall Event |
Penn Medicine |
1hr 05mins |
198 |
3 |
|
2021 Feb 02 |
5 |
Medium |
5 |
Dr. Elizabeth Howell, Chair of the Department of Obstetrics and Gynecology at Penn Medicine, hosts a town hall focused on the COVID vaccine and pregnancy. |
Vaccines |
2021 Feb 24 |
| 168 |
Immune Profiling in Patients with COVID-19 | Dr. John Wherry |
Penn Medicine |
21mins 29secs |
451 |
5 |
|
2020 Oct 08 |
5 |
Technical information |
5 |
Immune profiliing of Covid-19 patients |
Immunology |
2021 Feb 25 |
| 169 |
COVID Live Webinar Series: Vaccines, Immunity and T-Cells |
Survivor Corps HQ |
1hr 04mins |
1825 |
44 |
|
2020 Dec 18 |
5 |
Technical information |
5 |
Conversation on Vaccines, Immunity and T- Cells |
Vaccine |
2021 Feb 25 |
| 170 |
Dr. John Wherry: Deep Immune Profiling in SARS-CoV-2 Patients |
Human Vaccines Project |
1hr |
446 |
11 |
|
2020 Sep 11 |
5 |
Technical information |
5 |
Global COVID Lab Meeting with Dr. E. John Wherry, Director at the Institute for Immunology and Chair of the Department of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. His lab recently published a study in Science that uncovered distinct immunotypes in COVID-19 patients, which may have implications for the design of vaccines and therapeutics. |
Vaccine |
2021 Feb 25 |
| 171 |
Dr. Bette Korber: Spike mutations and recombination in SARS-CoV-2 pandemic viruses |
Human Vaccines Project |
1hr |
1004 |
17 |
|
2020 Jul 13 |
5 |
Technical information |
5 |
Dr. Bette Korber's new study suggesting a more transmissible form of SARS-CoV-2 is emerging due to mutations of the Spike (S) protein. Her findings have important implications for SARS-CoV-2 transmission, pathogenesis and immune interventions, and have been widely and sometimes not accurately reported in the press. In this Global COVID Lab Meeting Dr. Bette Korber presents her most important conclusions. |
Mutations |
2021 Feb 25 |
| 172 |
SARS-CoV-2 Vaccines and Variants |
The Rockefeller University |
1hr 30secs |
2124 |
40 |
3 |
2021 Feb 10 |
5 |
Technical information |
5 |
Hope is mounting as COVID-19 vaccines are deployed, but our optimism is tempered by the arrival of new viral strains that are more contagious and possibly vaccine resistant. In this webinar, virologist Paul Bieniasz and President Richard P. Lifton addressed critical questions about SARS-CoV-2 variants, such as "Why are variants suddenly appearing almost simultaneously, but thousands of miles apart?" and "Can lab research predict the types of variants that will emerge?" |
Mutations, Vaccines, variants |
2021 Feb 25 |
| 173 |
Fighting COVID-19 with Antibody Therapy |
The Rockefeller University |
1hr 11mins |
184 |
2 |
|
2021 Feb 09 |
5 |
Technical information |
5 |
In this webinar, Dr. Nussenzweig and President Rick Lifton discussed some of the most pressing questions about COVID-19 research and therapeutic discovery. For example, "What is the status of antibody therapies developed at Rockefeller?" and "Can antibody therapies protect against infection?" |
Immnology, therapeutics |
2021 Feb 25 |
| 174 |
Racing to Beat COVID-19: The Oxford Vaccine and Other Tales from the UK |
The Rockefeller University |
1hr 21mins |
7327 |
48 |
21 |
2020 Sep 24 |
5 |
Technical information |
5 |
Sir John Bell, a renowned biomedical scientist at the University of Oxford, is the leader of a rapidly advancing effort within this unprecedented campaign. Rockefeller University President Rick Lifton and Professor Bell discuss the extraordinary challenges involved in the development and international testing of new vaccines amid a global pandemic, as well as other medical measures needed to bring COVID-19 under control. |
Therapeutics |
2021 Feb 25 |
| 175 |
Jesse Bloom: "Interpreting the Evolution of SARS-CoV-2" |
HHMI Howard Hughes Medical Institute |
1hr 14mins |
430 |
|
|
2021 Mar 11 |
5 |
Technical information |
5 |
Jesse Bloom, an HHMI Investigator and associate professor in the Basic Sciences Division and in the Public Health Sciences Division at Fred Hutchinson Cancer Research Center. He uses computational biology and real-world data to build evolutionary models and examine different scales of viral evolution, from evolution within a single host to evolution on a global scale. |
Mutations, Evolution |
2021 Mar 14 |
| 176 |
March 1, 2021 ACIP Meeting - SARS-CoV-2 Variants - Consideration for vaccine |
Centers for Disease Control and Prevention (CDC) |
47mins |
1061 |
16 |
5 |
2021 Mar 06 |
5 |
Technical information |
5 |
Dr.Heather Scobie, CDR, talks about the SARS-CoV-2 variants and the efficacy of various vaccines on the variant strains |
Variants, Vaccine |
2021 Mar 14 |
| 177 |
WHO's Science in 5 on COVID-19: Evolution of the SARS-CoV-2 virus |
World Health Organization (WHO) |
4mins 31secs |
4549 |
62 |
23 |
2021 Mar 05 |
5 |
Easy |
5 |
WHO's Dr. Maria Van Kerkhove, talks about the latest information on the SARS-CoV-2 virus variants. |
Variants, Virus evolution |
2021 Mar 14 |
| 178 |
Virus closely related to SARS-CoV-2 found in horseshoe bats in Southeast Asia |
CGTN |
3mins 41secs |
12851 |
318 |
22 |
2021 Feb 28 |
5 |
Easy |
5 |
While the origin of the coronavirus has yet to be determined, researchers in Cambodia and Thailand have found a virus that's closely related to it in horseshoe bats. They're the first known relatives of the coronavirus to be found outside China. |
Virus evolution |
2021 Mar 14 |
| 179 |
Emergence and spread of a new SARS-CoV-2 Variant (501Y.V2) in South Afric |
DiscoverySA |
1hr 13mins |
128 |
1 |
|
2021 Mar 05 |
5 |
Technical information |
5 |
In this webinar, Professor Tulio de Oliveira and Doctor Richard Lessells, share about the South African Variant of SARS CoV-2, with meaningful insights on how it spread, the impact on the pandemic response as well as the clinical implications |
Variants |
2021 Mar 14 |
| 180 |
Procalcitonin's Role in Antibiotic Stewardship & SARS-CoV-2 Infection, Secondary Bacterial Infection |
SCCM |
1 hr |
91 |
5 |
|
2021 Mar 13 |
4 |
Technical information |
5 |
Dr.Michael Mansour and Dr.Natalie J. Atallah talks about the current approved clinical uses demonstrating PCT (Procalcitonin) utility in helping to differentiate bacterial versus viral infection in LRTI (lower respiratory track infections) and provide aid in antibiotic decision making |
Medicine, symptoms |
2021 Mar 14 |
| 181 |
The Science behind cPass™ |
Duke-NUS |
2mins 25secs |
40 |
1 |
|
2021 Mar 12 |
4 |
Technical information |
5 |
This video describes the science behind the SARS-CoV-2 antibody detection kit |
testing / diagnosis |
2021 Mar 14 |
| 182 |
Flowflex SARS-CoV-2 Antigen Rapid Test (Self-testing) |
ACON Laboratories, Inc |
2mins 25secs |
19 |
1 |
|
2021 Mar 13 |
4 |
Easy |
5 |
This video describes a self-testing SARS-CoV-2 Antigen Rapid Test. |
testing / diagnosis |
2021 Mar 14 |
| 183 |
Coronavirus Variants |
JAMA Network |
34mins 41secs |
29977 |
705 |
34 |
2021 Mar 05 |
5 |
Technical information |
5 |
Dr.John Moore, Professor of Virology, approaches for the optimal use of different COVID-19 vaccines . Issues of viral variants and viral efficacy. |
Variants, vaccines |
2021 Mar 14 |
| 184 |
Animation of SARS-CoV-2 entry into human host-cell. |
ThornLab |
1min 54 secs |
443 |
19 |
|
20201 Mar 09 |
5 |
Technical information |
5 |
Animation of SARS-CoV-2 entry into human cell |
Molecular biology |
2021 Mar 14 |
| 185 |
Ravindra Gupta: "SARS-CoV-2 evolution during treatment of chronic infection" |
HHMI Howard Hughes Medical Institute |
55mins 20secs |
401 |
|
|
2021 Feb 26 |
5 |
Technical information |
5 |
Ravi Gupta, Professor of Clinical Microbiology talks about Neutralising antibodies and SARS-CoV-2 evolution |
Microbiology |
2021 Mar 14 |
| 186 |
Michel Nussenzweig: "Fighting COVID-19 with Neutralizing Antibodies" |
HHMI Howard Hughes Medical Institute |
44mins 11secs |
457 |
|
|
2021 Jan 18 |
5 |
Technical information |
5 |
Dr.Michel Nussenzweig, professor of molecular immunology, talks of neutralising antibodies in combacting SARS-CoV-2 |
Immunology |
2021 Mar 14 |
| 187 |
What do SARS-CoV-2 Genomes Tell us About the Pandemic Spread? (CCDD ID Epi Seminar Series) |
Center for Communicable Disease Dynamics |
58mins 38secs |
97 |
3 |
|
2021 Mar 12 |
5 |
Technical information |
5 |
Dr. Tanja Stadler, Associate Professor at the Department of Biosystems Science and Engineering of the Swiss Federal Institute of Technology (ETH Zürich) in Basel, as well as a member of the Swiss National COVID-19 Science Task Force, talks about extracting information from SARS-CoV-2 genomes and about the pandeminc spread of Covid-19. |
Bioinformatics |
2021 Mar 16 |
| 188 |
COVID-19 in Brazil (CCDD ID Epi Seminar Series) |
Center for Communicable Disease Dynamics |
56mins |
51 |
1 |
|
2021 Mar 05 |
5 |
Technical information |
5 |
Dr. Marcia Castro, Andelot Professor of Demography and Chair of the Department of Global Health and Population at the Harvard T.H. Chan School of Public Health, as well as co-director of the Brazil Studies Program of the David Rockefeller Center for Latin American Studies (DRCLAS). Her research focuses on the development and use of multidisciplinary approaches to identify the determinants of infectious disease transmission in different ecological settings to inform control policies. |
Public health |
2021 Mar 16 |
| 189 |
Mayo Clinic Insights: What is a COVID-19 variant strain |
Mayo Clinic |
3mins 21secs |
406799 |
1.3K |
1.2K |
2021 Mar 02 |
5 |
Easy |
5 |
Dr. Binnicker provides information on the current COVID-19 variants and how we can help stop the spread of new strains in our communities. |
Variants |
2021 Mar 16 |
| 190 |
How the Johnson & Johnson SARS-CoV-2 vaccine works |
Color |
2mins 35secs |
2759 |
31 |
2 |
2021 Feb 28 |
5 |
Easy |
5 |
chief science officer, Alicia Zhou, Ph.D., on how the Johnson & Johnson vaccine works. |
Vaccines |
2021 Mar 16 |
| 191 |
Why is the Johnson & Johnson vaccine just as effective as the Moderna and Pfizer vaccines? |
University Hospitals |
1mins 05secs |
8425 |
70 |
3 |
2021 Mar 04 |
5 |
Easy |
5 |
Keith Armitage, MD, infectious disease physician and Medical Director, UH Roe Green Center for Travel Medicine & Global Health, discusses the important efficacy similarities between the Johnson & Johnson vaccine and the Moderna/Pfizer vaccines. |
Vaccines |
2021 Mar 16 |
| 192 |
Mayo Clinic Insights: What you should know about the Johnson & Johnson COVID-19 vaccine |
Mayo Clinic |
3mins 15secs |
36257 |
535 |
55 |
2021 Mar 12 |
5 |
Easy |
5 |
Dr. Swift discusses what you need to know about the new Johnson & Johnson COVID-19 vaccine. |
Vaccines |
2021 Mar 16 |
| 193 |
The COVID-19 Vaccines from Johnson & Johnson and AstraZeneca: What's in Them and How Do They Work? |
ARUP Laboratories |
11mins 09secs |
9541 |
132 |
7 |
2021 Mar 09 |
5 |
Easy |
5 |
The composition and delivery mechanism for the new classes of COVID-19 vaccines based on adenovirus from Johnson & Johnson and AstraZeneca with Dr. Jonathan Genzen, COO of ARUP Laboratories and an Associate Professor at the University of Utah School of Medicine. |
Vaccines |
2021 Mar 16 |
| 194 |
Johnson & Johnson COVID-19 Vaccine: Effectiveness, Side Effects and Differences Between Vaccines |
UC Davis Health |
2mins 44secs |
384779 |
1.8K |
945 |
2021 Mar 03 |
5 |
Easy |
5 |
Dr. Dean Blumberg, Chief of Pediatric Infectious Diseases at UC Davis Children's Hospital, explains how the new Johnson and Johnson COVID-19 vaccine works and answers common questions, including why it's different from other coronavirus vaccines, how side effects compare to Pfizer and Moderna vaccines |
Vaccines |
2021 Mar 16 |
| 195 |
What The COVID Vaccine Does To Your Body |
AsapSCIENCE |
5mins 22secs |
4207118 |
88K |
19K |
2020 Dec 08 |
5 |
Easy |
5 |
Is the coronavirus vaccine safe? Now that the first COVID19 vaccine from Pfizer is being released, how do mRNA vaccines work? |
Vaccines |
2021 Mar 16 |
| 196 |
Coronavirus Update 121: Johnson and Johnson Vaccine - Efficacy and Safety vs. Pfizer & Moderna |
MedCram - Medical Lectures Explained CLEARLY |
11mins 24secs |
390611 |
7.1K |
373 |
2021 Feb 05 |
5 |
Easy |
5 |
Professor Roger Seheult, MD explains the Johnson and Johnson / Janssen Pharmaceuticals vaccine candidate for COVID 19. Dr. Seheult illustrates how the Johnson & Johnson adenovirus vaccine works, the efficacy/safety (based on preliminary data), and how the vaccine compares to the Moderna vaccine and the Pfizer BioNTech vaccine. |
Vaccines |
2021 Mar 16 |
| 197 |
Johnson and Johnson Vaccine What You Need to Know |
Medicine with Dr. Moran |
8mins 16secs |
162726 |
2.6K |
104 |
2021 Feb 12 |
5 |
Easy |
5 |
Dr. Moran compares the Pfizer and Moderna vaccines to the new Johnson and Johnson and Janssen pharmaceuticals COVID-19 vaccine. The Johnson & Johnson vaccine was tested against the new COVID-19 variants in Brazil and South Africa. Dr. Moran answers whether you should opt for the Pfizer, Moderna, AstraZeneca or Johnson and Johnson vaccine. The costs of the Pfizer, modernity, AstraZeneca and Johnson & Johnson vaccines are compared. |
Vaccines |
2021 Mar 16 |
| 198 |
All Types of COVID-19 Vaccines, How They Work, Animation. |
Alila Medical Media |
5mins 55secs |
33989 |
665 |
17 |
2021 Jan 27 |
5 |
Easy |
5 |
How it works. mRNA vaccine (Pfizer, Moderna), DNA & Viral vector vaccines (Johnson & Johnson (J&J, JNJ), Oxford-AstraZeneca, Inovio, Sputnik V); protein/peptide vaccine (Novavax, EpiVacCorona), conventional inactivated (CoronaVac of Sinovac, Covaxin). Mechanism of each type of coronavirus vaccines explained. Vaccine-induced immune response as compared to natural immunity. |
Vaccines |
2021 Mar 16 |
| 199 |
Johnson & Johnson COVID-19 Vaccine Q&A with Dr. Brahm Segal |
Roswell Park Comprehensive Cancer Center |
13mins 13secs |
4445 |
54 |
4 |
2021 Mar 06 |
5 |
Easy |
5 |
Dr. Brahm Segal discusses the different types of COVID-19 vaccines. |
Vaccines |
2021 Mar 16 |
| 200 |
Johnson & Johnson COVID-19 Vaccine |
Mount Sinai Health System |
16mins 47secs |
328735 |
1.3K |
2.8K |
2021 Feb 12 |
5 |
Techincal information |
5 |
Dr. Dana Mazo discusses the Johnson & Johnson COVID-19 vaccine. |
Vaccines |
2021 Mar 16 |
| 201 |
Comparing Johnson & Johnson Janssen Covid-19 Vaccine to Pfizer and Moderna |
Medical College of Wisconsin |
2mins 13secs |
13506 |
105 |
20 |
2021 Mar 09 |
5 |
Easy |
5 |
MCW associate professor Dr. Ben Weston shares his knowledge on the benefits, development technology, and the safety and efficacy of the Johnson & Johnson/Janssen COVID-19 vaccine. |
Vaccines |
2021 Mar 16 |
| 202 |
The Pathophysiology of SARS CoV-2 - Angela Campbell & Ellen Hillegass |
MedBridge |
2mins 22secs |
95 |
1 |
|
2021 Feb 25 |
5 |
Easy |
5 |
Pathophysiology of SARS_CoV-2 |
Pathophysiology |
2021 Mar 16 |
| 203 |
Immunity Against SARS-CoV-2 and COVID-19 Vaccines |
Icahn School of Medicine |
1hr 01min |
66 |
2 |
1 |
2021 Mar 16 |
5 |
Technical information |
5 |
A Mount Sinai Morningside and Mount Sinai West Department of Medicine Grand Rounds presented by Florian Krammer, PhD, Professor of Microbiology |
Vaccines, Immunology |
2021 Mar 16 |
| 204 |
Notable variants of SARS-CoV-2 that emerged in late 2020 |
What the Science |
29secs |
33 |
6 |
|
2021 Mar 13 |
5 |
Easy |
5 |
Variants of SARS-CoV-2 |
Variants |
2021 Mar 16 |
| 205 |
B.1.526 a new SARS CoV-2 Variant in New York |
What the Science |
1min 24secs |
543 |
10 |
|
2021 Feb 27 |
5 |
Easy |
5 |
A new variant of the coronavirus, known as B.1.526, is spreading across New York City causing concerns among researchers regarding how it might affect the vaccination process.Research shows that this New York variant shares characteristics with the variants B.1.351 and P.1, identified in South Africa and Brazil respectively. |
Variants |
2021 Mar 16 |
| 206 |
Ryan Interviews Health care Expert About Coronavirus. Let's Learn How we can help each other. |
Ryan's World |
14min 49secs |
4884141 |
17k |
2.2k |
2020 Apr 17 |
5 |
Easy |
4 |
|
General |
2021 Mar 16 |
| 207 |
Scientific information about corona virus: simple straight science part I (English |
Kshitish Acharya |
16mins 12secs |
484 |
63 |
0 |
2020 Aug 15 |
5 |
Easy |
5 |
Simplified explaintion about viruses in general and how they make their entry into the cell. |
Basic science |
2021 Apr 09 |
| 208 |
Ayurveda vs. Modern medicine: Simple Straight Science, part 2 [ENGLSIH] |
Kshitish Acharya |
15mins 19secs |
309 |
50 |
0 |
2020 Aug 15 |
5 |
Easy |
5 |
Dr.Kshitish Acharya talks about the basic difference between Ayurveda and Modern Medicine |
Traditional medicin |
2021 Apr 09 |
| 209 |
Why COVID-19 Is Hitting Men Harder |
Johns Hopkins Bloomberg School of Public Health |
2 min |
552545 |
35 |
8 |
2020 Jul 10 |
5 |
Easy |
5 |
Sex Differences in COVID-19 |
General |
2021 May 04 |
| 210 |
Many Questions Remain About Pregnancy And COVID-19 |
WMAR-2 News |
3 min 40 sec |
659 |
1 |
0 |
2020 May 23 |
5 |
Easy |
5 |
Pregnant covid-19 patient |
General |
2021 May 04 |